Posted by Michael Wonder on 03 Nov 2022
BeiGene receives European Commission approval for Brukinsa (zanubrutinib) for the treatment of adults with marginal zone lymphoma
2 November 2022 - Brukinsa is the first and only Bruton’s tyrosine kinase inhibitor for marginal zone lymphoma approved in the European Union.
BeiGene today announced that the European Commission has granted marketing authorisation of Brukinsa (zanubrutinib) for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20 based therapy.
